BioMag Receives Second Patent on Its High Throughput Screening - Magnetic Testing Platform
News May 11, 2006
BioMag Corp., through its wholly owned subsidiary Biospectrum Technologies Inc., has announced that it has received its second patent from the U.S. Patent office on its High Throughput Screening - Magnetic Testing Platform (HTS-MTP) that is designed to produce both qualitative (yes/no) and quantitative (viral load) results from a single test.
Clayton Hardman, president and CEO of BioMag Corp., stated, "In addition to the HTS-MTP patent that was received from the U.S. Patent office in July of 2003, we have just received our second patent, further establishing our technology and enabling a broad spectrum of applications in which our product applies, in both medical testing and diagnostics."
"It is safe to say that our product is one of a kind in which can potentially revolutionize the diagnostic industry."
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019